StockData

RxSight, Inc. (RXST) company profile

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3074% below fair value
$5.32−0.06 (-1.12%)

Close on Nov 13, 2026Market cap $221.28MP/E –Yield –

About RxSight

Ophthalmic Goods, SIC 3851

RxSight, Inc. is a commercial-stage medical technology company that provides customized vision solutions to patients following cataract surgery. The company develops, manufactures, and markets the proprietary RxSight Light Adjustable Lens system, an adjustable intraocular lens technology. This system includes the Light Adjustable Lens, the Light Delivery Device, and associated accessories. The technology allows ophthalmic surgeons to modify lens power and astigmatic correction non-invasively through ultraviolet light treatments after surgical implantation, rather than relying exclusively on preoperative estimates. Its primary customers are ophthalmologists and cataract surgeons, as well as ophthalmic practices and ambulatory surgery centers.

The company focuses its commercial operations primarily in the United States through a direct sales team, clinical specialists, and field service personnel. Its sales target high-volume cataract surgeons who perform premium intraocular lens procedures. As of December 31, 2025, the company had an installed base of 1,134 Light Delivery Devices across ophthalmology practices. The provided text does not mention the location of the company's headquarters.

Summary of the business section of RxSight's latest annual report, written by StockData.

Company profile

Company

Legal name
RxSight, Inc.
Headquarters
Aliso Viejo, CA
Address
100 Columbia Street, Suite 120 92656
Phone
(949) 521-7822
Employees
461, Dec 31, 2025
Industry
Ophthalmic Goods
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Irvine, California

Stock & identifiers

Ticker
RXST
Exchange
Nasdaq
IPO date
Jul 30, 2021
Shares outstanding
42M, Jul 31, 2026
Public float
$503.80M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1111485
CUSIP
78349D107
ISIN
US78349D1072
FIGI
BBG00THX1YN4
Share class FIGI
BBG00THX1YQ1
EIN
94-3268801

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Aziz MottiwalaPresident and CEO, Director–
Eric WeinbergSee remarks536,419
Mark WilterdingChief Financial Officer25,049
Ilya GoldshlegerChief Operating Officer82,881
Ronald M. Kurtz MDChief Medical Officer836,385
Scott GainesChief Customer Officer17,428
Shelley B. ThunenSee remarks38,354
Bakker Juliet TammenomsDirector86,731
Robert J. PalmisanoDirector78,076
Julie AndrewsDirector78,076
Jesse Anderson CorleyDirector108,145
Robert Keith WarnerDirector78,076
Shweta ManiarDirector55,172
Tamara FountainDirector72,582
Raymond W. CohenDirector66,532
William J. Link PhdDirector96,140

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.65M-$2.16M$2.48M$93$76
FY2024$6.98M$5.12M$5.80M$306$76
FY2023$3.08M$11.80M$1.81M$358$72
FY2022$1.03M$1.25M$649.36K$113$77

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Ron Kurtz, M.D.
Chief Executive Officer, President and Director
$630.63K–$3.82M$202.94K$571$4.65M-33%
Shelley Thunen
Former Chief Financial Officer
$520.38K–$2.22M$108.85K$7.00K$2.86M-51%
Eric Weinberg
Chief Business Development Officer
$520.38K–$2.22M$108.85K$7.00K$2.86M-51%
Ilya Goldshleger, Ph.D.
Chief Operating Officer
$520.38K–$2.22M$108.85K$4.78K$2.85M-51%
Scott Gaines
Chief Customer Officer
$401.67K$448.68K$455.54K$64.63K$5.76K$1.38M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 30, 2021
Offer price
$16.00
Securities offered
7,350,000
Gross proceeds
$117.60M
Exchange
Nasdaq
First trading day
Jul 30, 2021
First-day close
$16.000.0%
Lock-up ends (est.)
Jan 26, 2022

“Per Share Total Initial public offering price $ 16.00 $ 117,600,000 Underwriting discounts and commissions(1) $ 1.12 $ 8,232,000 Proceeds, before expenses, to us $ 14.88 $ 109,368,000 (1) See the section titled “Underwriting” for a description of the compensation payable to the underwriters.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 461 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 30, 2021IPOInitial public offering priced (424B4 prospectus)
Jul 28, 2021ListingRegistration of securities on an exchange (Form 8-A)
Mar 20, 2014Name changeName changed from CALHOUN VISION INC to RxSight, Inc.

See a number that looks wrong?